Skip to main content

Year: 2019

Blade Runner Nexus -peliä ei julkaista vuoden 2019 puolella, yhtiö päivittää näkymiään

NEXT GAMES OYJ, YHTIÖTIEDOTE, 5.12.2019 klo 16:40Next Games jatkaa Blade Runner Nexus -pelin koemarkkinointia vuoden 2019 loppuun asti ja vuoden 2020 puolelle. Yhtiön tiedonantopolitiikan mukaisesti yhtiö ilmoittaa koemarkkinointivaiheen jatkamisesta, sillä yhtiön aiemmin ilmoittaman tavoitteen mukainen yhden pelin vuosittainen julkaisutahti ei pelin koemarkkinointivaiheen jatkamisen ansiosta täyty vuoden 2019 osalta.Yhtiö päivittää liiketoimintanäkymiään liikevaihdon osalta ja arvioi liikevaihdon pysyvän noin vuoden 2018 tasolla aiemmin arvioidun maltillisen kasvun sijasta.Lisätietoja:Saara BergströmMarkkinointi- ja viestintäjohtajainvestors@nextgames.com+358 (0)50 483 3896Next GamesNext Games (Helsinki Nasdaq First North: NXTGMS) on lisensoituihin peleihin keskittyvä mobiilipelien kehittäjä ja julkaisija sekä ensimmäinen Suomessa pörssiin...

Continue reading

Fastsættelse af rentetrigger for rentetilpasningsobligationer

DLR har afsluttet obligationssalget i forbindelse med refinansieringen af rentetilpasningslån med årlig rentetilpasning pr. 1. januar 2020 og har fastsat niveauet for rentetriggeren på de 1-årige rentetilpasningsobligationer i DKK og EUR, der kan udløse forlængelse af løbetiden ved næste års refinansiering.Flere oplysninger om rentetriggere kan ses på www.dlr.dk/investor. Oplysninger om obligationssalget i forbindelse med refinansieringerne kan ses samme sted.Spørgsmål vedrørende rentetrigger kan rettes til Fondschef Erik Bladt på telefon 33 42 07 37.Med venlig hilsenDLR Kredit A/SVedhæftet filFastsættelse af rentetrigger_20191205

Continue reading

Akers BioSciences, Inc. Announces Pricing of Approximately $8 Million Public Offering

Thorofare, New Jersey, Dec. 05, 2019 (GLOBE NEWSWIRE) — Akers Biosciences, Inc. (the “Company” or “we”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced the pricing of a public offering of 1,990,000 units. Each unit is comprised of one share of common stock (or common stock equivalent) and one preferred stock warrant to purchase one share of Series C Convertible Preferred Stock. The units are being offered at a public offering price of $4.00 per unit.H.C. Wainwright & Co. is acting as exclusive placement agent for the offering.The preferred stock warrants will be exercisable immediately at an exercise price of $4.00 per share of Series C Convertible Preferred Stock. Before any shares of Series C Convertible Preferred Stock can become convertible, Akers must receive stockholder approval of...

Continue reading

RAMM Pharma Corp. Welcomes Legalization of Medical Cannabis in Brazil

TORONTO, Dec. 05, 2019 (GLOBE NEWSWIRE) — RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or “RAMM”) (CSE: RAMM), a leader in plant-derived cannabinoid pharmaceutical products, welcomes the announcement by Brazil’s National Health Surveillance Agency (ANVISA) which establishes a legalized environment for the sale and consumption of cannabis for medical use, as announced on December 2, 2019. The new regulations will be posted to the Federal Official Gazette in the coming days and will take effect 90 days thereafter. The regulations were approved unanimously as outlined below:Medical cannabis products approved for sale by prescription through pharmacies and drug stores.Permitted products are restricted to products for oral and nasal use, in tablet or liquid form, as well as oil solutions.All cannabis...

Continue reading

Daktronics Announces Quarterly Cash Dividend per Share

BROOKINGS, S.D., Dec. 05, 2019 (GLOBE NEWSWIRE) — Daktronics, Inc. (NASDAQ – DAKT) announced today that its Board of Directors on December 4, 2019 approved a regular quarterly cash dividend of $0.05 per share.           The quarterly dividend will be payable on December 26, 2019, to shareholders of record as of the close of business on December 16, 2019.Although the Company intends to pay dividends for the foreseeable future, any and all subsequent dividends will be reviewed regularly and declared by the Board at its discretion.About Daktronics             Daktronics has strong leadership positions in, and is the world’s largest supplier of, large-screen video displays, electronic scoreboards, LED text and graphics displays, and related control systems. The company excels in the control of display systems, including...

Continue reading

Vislink Technologies Receives $1.5 Million in New Orders in Live Production, Military-Government and Satcom Markets

HACKETTSTOWN, NJ, Dec. 05, 2019 (GLOBE NEWSWIRE) — Vislink Technologies, Inc. (NASDAQ: VISL) announces that the Company has received $1.5 million in new orders in its live production, military-government and satcom markets. The new orders add to the $13 million order backlog that the company previously announced on Nov. 6, 2019.The live production orders were received from clients operating in the broadcast, sports and entertainment sectors for solutions including the HCAM 4K UHD, Vislink’s premium wireless camera system. The HCAM will be used to provide coverage from tier-1 sporting events including the Olympics and European Football Championships. Additional orders were for products including transmitters, receivers, broadcast digital microwave systems, antennas and related components.In the military-government sector, the new...

Continue reading

Misonix Announces Results of New Large Real-World Studies That Further Prove the Clinical Effectiveness of TheraSkin

FARMINGDALE, N.Y., Dec. 05, 2019 (GLOBE NEWSWIRE) — Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, announced today the recent publication of two new large real-world studies that further prove the clinical effectiveness of its all human split thickness skin allograft TheraSkin® for the treatment of complex wounds. Results of the studies were published in Wound Repair and Regeneration and International Wound Journal.“We are very pleased with the results of these two large retrospective propensity matched-cohort studies offering further proof that TheraSkin is a highly effective tool for clinicians treating hard to heal wounds,” stated Dr. Arti Masturzo, Chief Medical Officer at Misonix. “In...

Continue reading

Nova Leap Health Corp. Announces Non-Brokered Private Placement of Convertible Debentures

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREINHALIFAX, Nova Scotia, Dec. 05, 2019 (GLOBE NEWSWIRE) — NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or the “Company”), a 2019 TSX Venture 50™ ranked company focused on the home health care industry, will undertake a non-brokered private placement through the issuance of unsecured subordinated convertible debentures (the “Debentures”) for maximum gross proceeds of CAD$2 million (the “Offering”). The Debentures will mature five (5) years after the issue date (the “Maturity Date”) and will accrue interest at the rate of 8.0% per annum, payable semi-annually. At the holders’ option, the Debentures may be converted into common shares of Nova Leap at any time and from time...

Continue reading

Kinross to sell Lundin Gold shares for approximately CAD$150 million

TORONTO, Dec. 05, 2019 (GLOBE NEWSWIRE) — Kinross Gold Corporation (TSX:K; NYSE:KGC) (“Kinross”) announced today that it has agreed to sell its remaining 20,656,250 shares in Lundin Gold Inc. (“Lundin Gold”) to a syndicate of buyers for expected gross proceeds of approximately CAD$150 million.The syndicate of buyers includes a wholly-owned subsidiary of Newcrest Mining Limited and the Lundin Family Trust. The shares for sale represent approximately 9.2% of the issued and outstanding shares of Lundin Gold and are based on Lundin Gold’s latest publicly released information regarding the number of shares currently outstanding. Closing of the sale is expected to occur on or about December 9, 2019.Kinross is selling its Lundin Gold shares as part of its portfolio management strategy and to further strengthen its balance sheet.About...

Continue reading

Golden Matrix Reports Net Income of $545,888 on Record Revenues of $881,845 for the First Fiscal Quarter of 2020

LAS VEGAS, Dec. 05, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Golden Matrix Group Inc. (OTCPK: GMGI), a technology-driven company that designs and develops social gaming platforms, systems and gaming content, today announced that for the first fiscal (2020) quarter ended October 31, 2019, the company reported net income of $545,888, a 64.4% increase on net income of $331,999 in the first fiscal quarter ended October 31, 2018. Record revenues of $881,845 in fiscal Q1’20 represent a 38.1% improvement on revenues of $638,695 in fiscal Q1’19.Net profit margin was 62% in fiscal Q1’20 versus 52% in the like year-ago quarter. First quarter revenues of $881,845 were also an 11.2% increase on revenues of $792,807 recorded in the fourth fiscal quarter ended July 31, 2019 and mark the company’s seventh consecutive quarter of rising...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.